Literature DB >> 26423535

HLA-genotyping of clinical specimens using Ion Torrent-based NGS.

Jonathan C Barone1, Katsuyuki Saito2, Karl Beutner2, Maria Campo2, Wei Dong1, Chirayu P Goswami3, Erica S Johnson3, Zi-Xuan Wang3, Susan Hsu4.   

Abstract

We have evaluated and validated the NXType™ workflow (One Lambda, Inc.) and the accompanying TypeStream™ software on the Ion Torrent Next Generation Sequencing (NGS) platform using a comprehensive testing panel. The panel consisted of 285 genomic DNA (gDNA) samples derived from four major ethnic populations and contained 59 PT samples and 226 clinical specimens. The total number of alleles from the six loci interrogated by NGS was 3420. This validation panel provided a wide range of HLA sequence variations including many rare alleles, new variants and homozygous alleles. The NXType™ system (reagents and software) was able to correctly genotype the vast majority of these specimens. The concordance rate between SBT-derived genotypes and those generated by TypeStream™ auto-analysis ranged from 99.5% to 99.8% for the HLA-A, B, C, DRB1 and DQB1 loci, and was 98.9% for HLA-DPB1. A strategy for data review was developed that would allow correction of most of the few remaining typing errors. The entire NGS workflow from gDNA amplification to genotype assignment could be completed within 3 working days. Through this validation study, the limitations and shortcomings of the platform, specific assay system, and software algorithm were also revealed for further evaluation and improvement.
Copyright © 2015 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Genotyping; HLA class I, II; Isothermal amplification; Multiplex PCR; Next Generation Sequencing

Mesh:

Substances:

Year:  2015        PMID: 26423535     DOI: 10.1016/j.humimm.2015.09.014

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  7 in total

1.  Cataloguing experimentally confirmed 80.7 kb-long ACKR1 haplotypes from the 1000 Genomes Project database.

Authors:  Kshitij Srivastava; Anne-Sophie Fratzscher; Bo Lan; Willy Albert Flegel
Journal:  BMC Bioinformatics       Date:  2021-05-26       Impact factor: 3.169

Review 2.  A long road/read to rapid high-resolution HLA typing: The nanopore perspective.

Authors:  Chang Liu
Journal:  Hum Immunol       Date:  2020-05-01       Impact factor: 2.211

3.  Deciphering the fine nucleotide diversity of full HLA class I and class II genes in a well-documented population from sub-Saharan Africa.

Authors:  T Goeury; L E Creary; L Brunet; M Galan; M Pasquier; B Kervaire; A Langaney; J-M Tiercy; M A Fernández-Viña; J M Nunes; A Sanchez-Mazas
Journal:  HLA       Date:  2018-01       Impact factor: 4.513

Review 4.  Significance of functional disease-causal/susceptible variants identified by whole-genome analyses for the understanding of human diseases.

Authors:  Yuki Hitomi; Katsushi Tokunaga
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2017       Impact factor: 3.493

5.  Application of High-Throughput Next-Generation Sequencing for HLA Typing on Buccal Extracted DNA: Results from over 10,000 Donor Recruitment Samples.

Authors:  Yuxin Yin; James H Lan; David Nguyen; Nicole Valenzuela; Ping Takemura; Yung-Tsi Bolon; Brianna Springer; Katsuyuki Saito; Ying Zheng; Tim Hague; Agnes Pasztor; Gyorgy Horvath; Krisztina Rigo; Elaine F Reed; Qiuheng Zhang
Journal:  PLoS One       Date:  2016-10-31       Impact factor: 3.240

6.  Performance of a multiplexed amplicon-based next-generation sequencing assay for HLA typing.

Authors:  Chang Liu; Brian F Duffy; Eric T Weimer; Maureen C Montgomery; Jo-Ellen Jennemann; Rachel Hill; Donna Phelan; Lindsay Lay; Bijal A Parikh
Journal:  PLoS One       Date:  2020-04-23       Impact factor: 3.240

Review 7.  HLA Class I Molecules as Immune Checkpoints for NK Cell Alloreactivity and Anti-Viral Immunity in Kidney Transplantation.

Authors:  Burcu Duygu; Timo I Olieslagers; Mathijs Groeneweg; Christina E M Voorter; Lotte Wieten
Journal:  Front Immunol       Date:  2021-07-06       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.